236. Pseudohypoparathyroidism Clinical trials / Disease details

Clinical trials : 3 /  Drugs : 3 - (DrugBank : 2) / Drug target genes : 18 - Drug target pathways : 23

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04551170
(ClinicalTrials.gov)		July 13, 20209/9/2020Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years OldPhase 2 Study of Theophylline Treatment for PseudohypoparathyroidismPseudohypoparathyroidism;Albright Hereditary Osteodystrophy;Pseudohypoparathyroidism Type 1aDrug: Theophylline;Drug: PlaceboVanderbilt University Medical CenterNULLRecruiting2 Years12 YearsAll34Phase 2United States
2NCT02463409
(ClinicalTrials.gov)		June 201520/5/2015Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1aPseudohypoparathyroidism Type 1a;Albright Hereditary OsteodystrophyDrug: TheophyllineVanderbilt University Medical CenterMassachusetts General HospitalCompleted10 Years21 YearsAll6Phase 2United States